Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28251912 | 0.88 | LTA4H (0.72) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL28131751 | 0.86 | LTA4H (0.64) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL381565 | 0.86 | LTA4H (0.50) | LTA4HMAOBCYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL2027109 | 0.86 | LTA4H (0.69) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL5158250 | 0.83 | LTA4H (0.60) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL26949212 | 0.82 | LTA4H (0.64) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL11289347 | 0.81 | LTA4H (0.62) | LTA4HMAOBCYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL7282070 | 0.81 | LTA4H (0.62) | LTA4HMAOBTAAR1L3MBTL1TDP1 | |
| SCHEMBL21227008 | 0.80 | LTA4H (0.56) | LTA4HMAOBTAAR1CYP11B1CYP11B2 | |
| SCHEMBL254705 | 0.79 | KEAP1 (0.63) | LTA4HMAOBCYP11B1CYP11B2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133042-A1 | Diphosphines | BROWN JOHN MICHAEL (GB) | 2004-07-08 | — | — | US | claimed |
| EP-1124833-B1 | DIPHOSPHINES | ISIS INNOVATION (GB) | 2003-01-08 | — | — | EP | claimed |
| EP-1124833-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026220-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2000-05-11 | — | — | WO | claimed |
| US-20040133042-A1 | Diphosphines | BROWN JOHN MICHAEL (GB) | 2004-07-08 | — | — | US | disclosed |
| US-6706926-B1 | ENANTIOSELECTIVE HYDROGENATION CATALYSTS | ISIS INNOVATION LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1124833-B1 | DIPHOSPHINES | ISIS INNOVATION (GB) | 2003-01-08 | — | — | EP | disclosed |
| EP-1124833-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026220-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133042-A1 | Diphosphines | SIGMAR1, SSR4, LBR | LTA4H 2699/4885MAOB 4527/4885TAAR1 2759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.